Clinical data from investigator-initiated trials in 20 patients with multiple autoimmune diseases show allogeneic CAR-T QT-019B was generally well tolerated and demonstrated encouraging efficacy –– QT ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...

Kymera shows strong KT-621 Phase 1b efficacy, solid safety, platform validation, cash runway and growth potential in key ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

When pressure rises, broad guidance is useless. Teams need a repeatable sequence they can follow when deadlines compress or ...

An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. CLINUVEL PHARMACEUTICALS LTD has announced a significant expansion ...

Mycosis fungoides, the most prevalent CTCL subtype, accounts for the majority of cases. Although early-stage disease has a five-year survival rate of roughly 88%, it is a chronic cancer with ...

For decades, the state has offered limited avenues for rehabilitation and shorter sentences. It’s time lawmakers fix it.

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

Citius Pharmaceuticals ( ($CTXR) ) has issued an update. On December 1, 2025, Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, ...